BioCardia (NASDAQ:BCDA) Posts Earnings Results, Beats Estimates By $0.01 EPS

BioCardia (NASDAQ:BCDA) announced its quarterly earnings results on Thursday. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.01, FiscalAI reports.

BioCardia Stock Performance

NASDAQ BCDA traded down $0.10 during trading hours on Thursday, reaching $0.83. The company’s stock had a trading volume of 288,420 shares, compared to its average volume of 996,821. The stock has a market cap of $12.50 million, a PE ratio of -1.29 and a beta of 0.69. BioCardia has a fifty-two week low of $0.66 and a fifty-two week high of $1.80. The company’s 50-day moving average is $1.02 and its two-hundred day moving average is $1.06.

Analyst Ratings Changes

A number of analysts recently commented on the stock. HC Wainwright reissued a “buy” rating on shares of BioCardia in a report on Monday, August 24th. Wall Street Zen raised shares of BioCardia from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of BioCardia in a research report on Thursday, October 15th. Finally, Zacks Research raised BioCardia from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $25.00.

About BioCardia

BioCardia, Inc. is a biotechnology company focused on developing regenerative cell therapies and delivery systems for the treatment of cardiovascular diseases. The company’s programs are designed to address conditions in which damaged or poorly functioning heart tissue may benefit from cellular therapy. BioCardia’s principal product candidates include CardiAMP Cell Therapy, an autologous treatment that uses a patient’s own bone marrow-derived cells, and CardiALLO Cell Therapy, an investigational allogeneic therapy based on mesenchymal precursor cells from a donor source.